Publication | Open Access
456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
13
Citations
0
References
2022
Year
Tumor BiologyInhibitor Gsk3326595OncologyMedicinePathologyCancer Cell BiologyAdvanced Solid TumorsMolecular OncologyAnti-cancer AgentTumor SuppressorPharmacologyCancer Research
No additional data available for this publication yet. Check back later!